Darzalex (daratumumab) Letter of Medical Necessity
Darzalex (daratumumab) prior authorization requires precise specification of the regimen, line of therapy, and clinical rationale for the chosen combination.
FDA-Approved Indications
- ● multiple myeloma (multiple lines and combinations)
- ● AL amyloidosis
Why Darzalex Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Line of therapy not documented
- 2. Combination regimen not specified
- 3. Subcutaneous (Faspro) vs IV not justified
What to Include in a Darzalex Letter of Medical Necessity
Document myeloma diagnosis with cytogenetics, stage, prior therapies and outcomes, ECOG, the planned regimen (e.g., DRd, DVd, DKd), and route (IV vs subQ Faspro).
Key clinical evidence to cite:
- ✓ POLLUX, CASTOR, ALCYONE, MAIA, GRIFFIN
Relevant guidelines:
- 📖 NCCN Multiple Myeloma Guidelines
Darzalex Prior Authorization Criteria
Standard criteria across major US payers for Darzalex. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Darzalex
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Darzalex Prior Authorization FAQ
Why was my Darzalex prior authorization denied?
The most common denial reasons for Darzalex are: Line of therapy not documented; Combination regimen not specified; Subcutaneous (Faspro) vs IV not justified.
What should a Darzalex Letter of Medical Necessity include?
Document myeloma diagnosis with cytogenetics, stage, prior therapies and outcomes, ECOG, the planned regimen (e.g., DRd, DVd, DKd), and route (IV vs subQ Faspro).
Which payers cover Darzalex?
Darzalex is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.